drugset / Trial / NCT00511797

SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study

NCT00511797

Phase 2/3 Completed 249 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate efficacy of drospirenone for dysmenorrhea.

Timeline

Start
2007-07
Primary completion
2009-01
Completion
2009-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject drospirenone Unknown 1 mg Oral
Subject drospirenone Unknown 2 mg Oral
Subject drospirenone Unknown 3 mg Oral
Subject ethinyl estradiol Small molecule 20 ug Oral

Indications